Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research (AACR) Annual Meeting 2019, which is being held from March 29 to April 3, 2019 at the Georgia World Congress Center in Atlanta, Georgia.
‘We’re looking forward to sharing preclinical data demonstrating the promise of our lead immunotherapy candidates, bempegaldesleukin and NKTR-255, in a variety of liquid and solid tumor models, including lymphoma, colon carcinoma and osteosarcoma,’ said Jonathan Zalevsky, Ph.D., Senior Vice President and Chief Scientific Officer at Nektar. ‘Collectively, these data suggest that bempegaldesleukin and NKTR-255 may work synergistically with other therapies to activate or amplify the body’s immune response to tumor cells, and we believe these combination approaches have the potential to improve immunotherapy treatment outcomes.’
Details on the Poster Presentations:
Abstract #2256/Poster Board #15 (bempegaldesleukin)Title: ‘Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models’, Granum, S., et al.
Session: Clinical Research – Combination Immunotherapies 1
Date:Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 19
Session: Clinical Research – Combination Immunotherapies 1
Date:Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 19
Abstract #3265/Poster Board #15 (NKTR-255)Title: ‘NKTR-255, a polymer-conjugated IL-15 enhances anti-tumor NK cell responses and synergizes with monoclonal antibodies to provide long-term survival in human lymphoma model’, Miyazaki, T., et al.
Session: Immunology – Novel Immunomodulatory Agents 1
Date:Tuesday, April 2, 2019, 8:00 – 12:00 p.m. Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25
Session: Immunology – Novel Immunomodulatory Agents 1
Date:Tuesday, April 2, 2019, 8:00 – 12:00 p.m. Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25
Abstract #3210/Poster Board #20 (bempegaldesleukin)Title: ‘A potential immunotherapeutic approach for the treatment of osteosarcoma’,Wahba, A., et al.
Session: Immunology – Combination Immunotherapies 2
Date:Tuesday, April 2, 2019, 8:00 a.m. – 12:00 p.m. Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 23
Session: Immunology – Combination Immunotherapies 2
Date:Tuesday, April 2, 2019, 8:00 a.m. – 12:00 p.m. Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 23
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.